Impact of HTLV-1 infection on clinicopathological characteristics and tumour immune microenvironment in colorectal cancer
Open Access
- 20 March 2025
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 487 (4) , 853-863
Abstract
Recent advances in anti-cancer therapy have indicated the significance of the tumour immune microenvironment in tumour progression and resistance to anti-cancer therapy. This study investigated primary colorectal cancer (CRC) tissues resected from 180 cases in a single institute in a region highly endemic for human T-cell leukaemia virus type 1 (HTLV-1) carriers. Among those 180 cases, 35 HTLV-1 carriers were identified. CRC patients who were HTLV-1 carriers were significantly older (mean age: 76.9 vs. 72.7 years, P = 0.0341), with a lower incidence of lymph node metastases (pN0: 91% vs. 65%, P = 0.0085), and lower tumour stages (stage III or IV: 11% vs. 36%, P = 0.0117) compared to non-carriers. HTLV-1 carriers tended to show a lower incidence of relapse, although the difference was not significant ( P = 0.2272). The density of forkhead box P3-positive regulatory T cells (Tregs) was significantly higher in HTLV-1 carriers (median density: 132 vs. 89 cells/mm 2 , P = 0.0051). In situ hybridisation showed cells positive for HTLV-1 basic leucine zipper factor , likely representing lymphocytes located in stroma around the cancer nest. Our findings indicate that lymph node metastasis was significantly suppressed in CRC patients infected with HTLV-1. Since HTLV-1 infection reportedly impairs the immunosuppressive functions of Tregs, anti-cancer immune responses are potentially enhanced in CRC patients who are HTLV-1 carriers.Keywords
Funding Information
- Kumamoto University
This publication has 48 references indexed in Scilit:
- FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancerImmunologic Research, 2015
- Current prevalence of HTLV‐1 in Japan as determined by screening of blood donorsJournal of Medical Virology, 2011
- A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4+FOXP3+ regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervixCellular & Molecular Immunology, 2010
- Clinical impact of tumor‐infiltrating lymphocytes for survival in stage II colon cancerCancer, 2010
- Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature reviewThe Journal of Pathology, 2010
- Intratumoral CD8+ T/FOXP3+ cell ratio is a predictive marker for survival in patients with colorectal cancerCancer Immunology, Immunotherapy, 2009
- Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription FactorImmunity, 2009
- Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancerEuropean Journal of Cancer, 2008
- Human T-lymphotropic virus type-I infection, survival and cancer risk in southwestern Japan: a prospective cohort studyCancer Causes & Control, 2003
- Inhibitory effect of maternal antibody on mother‐to‐child transmission of human T‐lymphotropic virus type IInternational Journal of Cancer, 1991